As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications on pediatric CML and from LMICs.

Read Professor Hughes' CML publications of the month: January 2026

Clinical CML papers

• Randomized phase 3 trial of Ropeginterferon alpha-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)
  Burchert A et al. Leukemia, January 2026 (epub ahead of print) – open access publication
  
• Ponatinib for CML patients in routine clinical practice: the PONDEROSA study
  Schenk T et al. Ann Hematol, January 2026 – open access publication
  
• Risk factors and reasons for switching from front-line therapy in the Italian CML network: A cohort study
  Breccia M et al. Br J Haematol, January 2026 (epub ahead of print)
• Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results
  Réa D et al. Leukemia, January 2026 (epub ahead of print)
• Management of chronic myeloid leukemia during pregnancy: Review of evidence and treatment algorithm
  Haddad FG et al. Clin Lymphoma Myeloma Leuk, January 2026
• Real-world outcomes with low-dose dasatinib (50 mg) in imatinib-resistant chronic myeloid leukemia chronic-phase: A retrospective analysis of efficacy and safety
  Gangadaran N et al. Cancer Rep (Hobokken), January 2026 – open access publication
• Evaluating the safety of combining tyrosine kinase inhibitors with anticoagulants in chronic myeloid leukemia: A systematic review
  Gameil A et al. Oncology, January 2026 (epub ahead of print) – open access publication
• One-year consolidation with ponatinib 15 mg in chronic myeloid leukemia on deep molecular response with imatinib
  Pérez-Lamas L et al. Ann Hematol, January 2026 – open access publication
  
• Prediction of relapse after discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia
  Ross DM. Leuk Lymphoma, January 2026 (epub ahead of print)
• Introduction to a How I Treat series on chronic myeloid leukemia
  Gotlib J. Blood January 2026
• How I treat advanced phases of CML
  Mauro MJ. Blood, January 2026
• How I evaluate and treat resistance and relapse in CML
  Soverini S and Castagnetti F. Blood, January 2026
• How I individualize frontline treatment for chronic phase CML
  Leyte-Vidal A and Shah NP. Blood, January 2026
• How I approach hematopoietic stem cell transplantation for CML in a TKI world
  Chalandon Y et al. Blood, January 2026
• How I manage chronic myeloid leukemia during pregnancy 
  Abruzzese E, Chelysheva E. Blood January 2026
• Advances of next-generation STAMP inhibitors in chronic myeloid leukemia
  Costa A and Breccia M. Expert Opin Investig Drugs, January 2026 
• Drug resistance in chronic myeloid leukemia: The involvement of Galectin-1 and Galectin-3
  Yildirim C. Mol Biol Rep, January 2026
• Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow
  Patterson SD et al. Leukemia, January 2026 (epub ahead of print) – open access publication

Scientific CML papers

• Hsp-70 Bim interaction mediated mitophagy as a potential therapeutic target for CML stem cells
  Song T et al. Stem Cell Reports, January 2026 – open access publication

Pediatric CML papers

• How I treat chronic myeloid leukemia in children and adolescents
  Chen J et al. Blood, January 2026
  
• Predictors of response to imatinib therapy and long-term outcomes in pediatric and adolescent patients with chronic myeloid leukemia
  Saha S et al. Cancer Rep (Hobokken), January 2026 – open access publication

LMIC papers

• Next-generation sequencing from chronic myeloid leukemia dried blood spots: Insights and implications for global oncology
  Oehler VG et al. Leukemia, January 2026 (epub ahead of print)
  
• Impact of bone marrow fibrosis on the outcomes of chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors
  Fayyaz F et al. Indian J Hematol Blood Transfus, January 2026